

Supplementary material has been published as submitted. It has not been copyedited or typeset by Acta Oncologica.

Supplementary Material

Supplementary Table 1. Characteristics of lymphoma patients diagnosed with aggressive lymphoma subtypes before (2017-2019) and during (2020 and 2021) the COVID-19 pandemic.

	Year of diagnosis					
	2017-2019		2020		2021	
	N(%)		N(%)		N (%)	
Total	3,055		1,019		982	
Median age (IQ range)	70	(58,78)	71	(56,79)	72	(59,79)
Age, categorized (years)						
<70	1,441	(47.2)	478	(46.9)	417	(42.5)
70-85	1,371	(45.0)	466	(45.7)	479	(48.8)
>85	238	(7.8)	75	(7.4)	86	(8.8)
Sex						
Male	1,860	(60.9)	600	(58.9)	605	(61.6)
Female	1,195	(39.1)	419	(41.1)	377	(38.4)
Performance status						
Asymptomatic	1,422	(46.5)	477	(46.8)	435	(44.3)
Ambulatory	971	(31.8)	313	(30.7)	318	(32.4)
Bedbound <50%	304	(10.0)	100	(9.8)	101	(10.3)
Bedbound >50%	189	(6.2)	76	(7.5)	67	(6.8)
Bedbound	107	(3.5)	26	(2.6)	43	(4.4)
Missing	62	(2.0)	27	(2.6)	18	(1.8)
Stage						
Ann Arbor I	566	(18.5)	160	(15.7)	149	(15.2)
Ann Arbor II	589	(19.3)	188	(18.4)	167	(17.0)
Ann Arbor III	512	(16.8)	158	(15.5)	152	(15.5)
Ann Arbor IV	1,188	(38.9)	406	(39.8)	409	(41.6)
Missing	200	(6.5)	107	(10.5)	105	(10.7)
Elevated LDH						
No	1,253	(41.0)	421	(41.3)	416	(42.4)
Yes	1,636	(53.6)	537	(52.7)	526	(53.6)
Missing	166	(5.4)	61	(6.0)	40	(4.1)
Active Treatment						
No	362	(11.9)	109	(10.7)	124	(12.6)
Yes	2,611	(85.5)	901	(88.4)	851	(86.7)
Missing	82	(2.7)	9	(0.9)	7	(0.7)
Subtype						
DLBCL	1,753	(57.4)	584	(57.3)	566	(57.6)
T-cell	375	(12.3)	126	(12.4)	109	(11.1)
HL	457	(15.0)	152	(14.9)	157	(16.0)
MCL	342	(11.2)	108	(10.6)	121	(12.3)

Short Report

Aggressive NOS	128	(4.2)	49	(4.8)	29	(3.0)
----------------	-----	-------	----	-------	----	-------

DLBCL=Diffuse Large B-cell Lymphoma, TCL= T-cell Lymphoma, HL = Hodgkin Lymphoma, MCL= Mantle cell lymphoma, NOS= Not otherwise specified IQ= Interquartile

Supplementary Table 2. Characteristics of lymphoma patients diagnosed with indolent lymphoma

subtypes before (2017-2019) and during (2020 and 2021) the COVID-19 pandemic.

	Year of diagnosis					
	2017-2019		2020		2021	
	N (%)		N (%)		N (%)	
Total	2,138		672		775	
Median age (IQ range)	71	(61,78)	72	(61,78)	73	(63,80)
Age, categorized (years)						
<70	953	(44.7)	302	(44.9)	304	(39.2)
70-85	1,029	(48.2)	320	(47.6)	408	(52.6)
>85	151	(7.1)	50	(7.4)	63	(8.1)
Sex						
Male	1,184	(55.4)	377	(56.1)	437	(56.4)
Female	954	(44.6)	295	(43.9)	338	(43.6)
Performance status						
Asymptomatic	1,451	(67.9)	440	(65.5)	498	(64.3)
Ambulatory	527	(24.6)	177	(26.3)	212	(27.4)
Bedbound <50%	82	(3.8)	30	(4.5)	30	(3.9)
Bedbound >50%	27	(1.3)	12	(1.8)	11	(1.4)
Bedbound	11	(0.5)	3	(0.4)	2	(0.3)
Missing	40	(1.9)	10	(1.5)	22	(2.8)
Stage						
Ann Arbor I	458	(21.4)	146	(21.7)	146	(18.8)
Ann Arbor II	196	(9.2)	71	(10.6)	69	(8.9)
Ann Arbor III	301	(14.1)	93	(13.8)	103	(13.3)
Ann Arbor IV	983	(46.0)	292	(43.5)	390	(50.3)
Missing	200	(9.4)	70	(10.4)	67	(8.6)
Elevated LDH						
No	1,462	(68.4)	452	(67.3)	530	(68.4)
Yes	555	(26.0)	173	(25.7)	192	(24.8)
Missing	121	(5.7)	47	(7.0)	53	(6.8)
Active Treatment						
No	1,039	(48.6)	355	(52.8)	407	(52.5)
Yes	1,044	(48.8)	316	(47.0)	367	(47.4)
Missing	55	(2.6)	1	(0.2)	1	(0.1)
Subtype						
FL	772	(36.1)	245	(36.5)	282	(36.4)
LPL	360	(16.8)	125	(18.6)	142	(18.3)
MZL	430	(20.1)	148	(22.0)	165	(21.3)
SLL	157	(7.3)	30	(4.5)	50	(6.5)
NLPHL	38	(1.8)	16	(2.4)	7	(0.9)
Indolent, NOS	381	(17.8)	108	(16.1)	129	(16.6)

Short Report


FL = Follicular lymphoma, LPL = lymphoplasmacytic lymphoma, MZL= Marginal Zone Lymphoma SLL=Small Lymphocytic Lymphoma, NLPHL=Nodular Lymphocyte Predominant Hodgkin Lymphoma, NOS= Not otherwise specified IQ= Interquartile

Supplementary Table 3. Incidence rates of lymphoma per 100 000 person-years before (2017-2019), and during (2020 and 2021) the COVID-19 pandemic, and incidence rate ratios (IRR) with 95% confidence intervals (CI), comparing the pandemic years to the pre-pandemic period (reference) by type of lymphoma and age.

	Incidence rate per 100,000 person-years			IRR (95% CI)		
	2017-2019	2020	2021	2017-2019	2020	2021
All Lymphomas	22.9	22.3	23.3	1 (ref)	0.97 (0.92, 1.02)	1.02 (0.97, 1.07)
Age<70	12.6	12.4	11.7	1 (ref)	0.98 (0.91, 1.06)	0.93 (0.86, 1.01)
Age 70-84	69.9	63.9	72.1	1 (ref)	0.91 (0.84, 0.99)	1.03 (0.96, 1.11)
Age 85+	67.9	71.8	78.1	1 (ref)	1.06 (0.90, 1.25)	1.15 (0.98, 1.35)
Aggressive	12.7	12.5	12.0	1 (ref)	0.98 (0.92, 1.06)	0.94 (0.88, 1.01)
Age<70	7.3	7.2	6.3	1 (ref)	0.99 (0.89, 1.09)	0.86 (0.77, 0.96)
Age 70-84	37.0	34.3	35.7	1 (ref)	0.92 (0.83, 1.03)	0.96 (0.87, 1.34)
Age 85+	37.4	41.1	40.0	1 (ref)	1.10 (0.88, 1.37)	1.07 (0.85, 1.33)
Indolent	8.9	8.2	9.5	1 (ref)	0.93 (0.85, 1.01)	1.06 (0.98, 1.16)
Age<70	4.8	4.6	4.6	1 (ref)	0.94 (0.83, 1.07)	0.94 (0.83, 1.07)
Age 70-84	28.0	24.2	30.7	1 (ref)	0.87 (0.76, 0.98)	1.10 (0.98, 1.23)
Age 85+	23.6	24.3	28.6	1 (ref)	1.03 (0.78, 1.37)	1.21 (0.93, 1.58)

Supplementary Figure 1a-c. The proportion of patients with stage I, II, III and IV per 6-months 2017-2021 for a) all lymphoma patients, b) aggressive lymphomas and c) Indolent lymphomas


Short Report



*The dashed line marks the beginning of the pandemic year 2020

Short Report

Supplementary Figure 2a-c. The proportion of patients with active treatment, no active treatment and missing per 6-months 2017-2021 for a) all lymphoma patients, b) aggressive lymphomas and c) Indolent lymphomas



*The dashed line marks the beginning of the pandemic year 2020